INDIA – Goa-based diagnostics chain Molbio Diagnostics has introduced its novel test for the differential diagnosis of the H3N2 and H1N1 virus.
Truenat H3N2/H1N1 is the first point-of-care Real-Time PCR test that aids in the confirmatory diagnosis of Influenza infections and it provides sample-to-result in an hour.
In a press release, Sriram Natarajan, CEO, Founder, and Director of Molbio Diagnostics, said: “The launch of Truenat H3N2/H1N1 further strengthens Molbio’s product portfolio by providing complete testing solutions for respiratory illnesses.”
Molbio’s patented Truenat technology, a point-of-care, portable, battery-operated Real-Time PCR platform, can screen over 40 diseases with a sample-to-result time of 60 minutes.
Truenat offers a game-changing solution for screening over 40 diseases, including COVID-19, TB, HCV, HBV, HIV, HPV, Dengue, Malaria, Influenza, Nipah, and typhoid, just to name a few.
Following regulatory approval by the Central Drugs Standard Control Organization (CDSCO), Molbio Diagnostics has released the Truenat H3N2/H1N1 into the Indian market.
The novel test is set to be deployed across over 3,500 Primary Health Centres (PHCs) and Community Health Centres (CHCs) and over 1,200 private labs and hospitals across India.
Molbio Diagnostics claims that the RT-PCR test, performed on the existing Truenat machine, will make it possible for patients to obtain a quick diagnosis at all levels of the healthcare chain.
“The multi-disease testing capability of the Truenat platform keeps healthcare facilities prepared to combat all kinds of pandemics and disease outbreaks at an early stage,” stated Sriram Natarajan.
The diagnostics product launch follows the surge in viral infections caused by H3N2, Covid-19, and swine flu across states and union territories of India.
As of 9th March 2023, a total of 3,038 laboratory-confirmed cases of various subtypes of Influenza including H1N1 and H3N2 have been reported by states in India
These viruses, spread through the air, have the ability for sustained human-to-human transmission, which can potentially cause an influenza pandemic.
The introduction of Truenat H3N2/H1N1 will allow clinicians to rapidly test for influenza infections as a first-line test and ultimately, improve patient outcomes.
“Going forward, Molbio will continue to bring innovative solutions for better patient management and appropriate treatment of the disease,” stated Natarajan reaffirmed to the health consumers.
The product development comes shortly after Molbio Diagnostics bought a 70 percent stake in Prognosys Medical Systems, a market leader in digital radiology and imaging equipment.
The acquisition of Prognosys Medical Systems will allow Molbio Diagnostics to expand its regional presence in specialized diagnostics.
The collaboration aligns with Molbio’s commitment to bringing a wide range of cost-effective, high-quality point-of-care solutions for hospitals and clinical laboratories.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
